Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
May 02, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
March 02, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva...
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
February 23, 2022 08:49 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
December 20, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
December 09, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
November 15, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases Results will be featured in a...
Intercept to Present at Upcoming Investor Conferences
November 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 03, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows...
Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
November 02, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups Poster presentations describe...
Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
October 27, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...